InfuSystems Holdings, Inc. · AMEX:INFU
InfuSystems — HAPC — SPAC Merger (October 2006)
13 slides from InfuSystems's SPAC merger presentation, Oct 5, 2006
Slide 1: Disclosure
Disclosure The attached presentation was filed with the Securities and Exchange Commission (“SEC”) as part of the Form 8–K filed by HAPC, Inc. (“HAPC”) on October 5, 2006. HAPC is holding presentations for its stockholders regarding its purchase of InfuSystem, Inc. (“InfuSystem”). A copy of the comp
Slide 2: Safe harbor
Safe harbor This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, about HAPC, InfuSystem and their combined business after completion of the proposed transaction. Forward-looking statements are statements that are not his
Slide 3: Acquisition details
Acquisition details Buyer: HAPC, Inc. (OTCBB: HAPN) Target: InfuSystem, Inc., a leading provider of ambulatory pumps and services to medical oncologists in the United States. Seller: I-Flow Corporation (NASDAQ: IFLO) Consideration: $140 million (subject to certain working capital adjustments as set
Slide 4: Key facts
Key facts A leading, independent provider of ambulatory infusion pumps and services to oncologists and cancer patients; primarily focused on treatment of colorectal cancers Headquartered in Madison Heights, MI (near Detroit) Approximately 111 employees Strong Financial Performance - $29 million of r
Slide 5: Investment highlights
As discussed in the following slides Investment highlights Leader in growing market Unique business model Compelling value proposition Competitive advantages Strong relationships with physician offices and payors Opportunity to expand to other cancer treatments Strong growth and profit margins
Slide 6: Leader in growing market
Leader in growing market 148,610 estimated new cases of colorectal cancer (“CRC”) in the U.S. in 2006 Continuous infusion regimens are achieving increased acceptance and are becoming a market standard chemotherapy for CRC Introduction of CRC treatment protocols FOLFOX (Sanofi) and FOLFIRI (Pfizer) i
Slide 7: Representative growth of continuous infusion
$130 $194 $368 $932 $1,517 $1,750 Representative growth of continuous infusion Source: Arrowhead Publishers, 2006 $- $200 $400 $600 $800 $1,000 $1,200 $1,400 $1,600 $1,800 $2,000 Increasing usage of FOLFOX protocol Sales of Eloxatin (Oxaliplatin) utilized in FOLFOX protocol with 5-FU and leucovorin
Slide 8: Compelling value proposition
Compelling value proposition Physicians Patients Payors Professional service fees Better patient outcomes Continues relationship with patient Less administrative demands Lower costs Better patient outcomes Continuity of care Reduces side effects Comfort and convenience Lower cost
Slide 9: Competitive Advantages
Regional DME Providers No significant scale Limited pump selection Limited insurance contracts Hospital Other hospitals unlikely to support competing hospitals Limited capital budgets Home care Takes revenue from physician office More costly for patients and payors Less convenient for patients Physi
Slide 10: Strong relationships with physician offices and payors
Strong relationships with physician offices and payors Relationships with approximately 60% of oncology practices - Opportunity to penetrate deeper within practices (more doctors) and expand product offerings Contracts covering approximately 65% of managed care “lives” - Include Aetna, PacifiCare, H
Slide 11: Expansion opportunities
Expansion opportunities Continuous infusion therapies may be extended to other cancers - Liver cancer and Hodgkins disease are growing parts of InfuSystem’s business - Drugs approved for lung, gastric, breast, leukemia, non-Hodgkins lymphoma, and other cancers - Several new drugs in development Pote
Slide 12: Strong growth and profit
US $ in millions $13.0 $19.3 $28.5 $15.7 $3.4 $7.1 $13.6 $7.2 $1.1 $2.9 $5.1 $2.9 $- $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 $14.0 $16.0 June 06 YTD 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% $- $5.0 $10.0 $15.0 $20.0 $25.0 $30.0 June 06 YTD Strong growth and profit $- $1.0 $2.0 $3.0 $4.0 $5.0 $6.0 June 06 YT
Slide 13: Annex 1: EBITDA reconciliation
Annex 1: EBITDA reconciliation General and administrative expenses do not include overhead costs associated with administrative services and corporate oversight that have historically been provided by I-Flow Corporation, InfuSystem’s parent, at no charge to InfuSystem. Upon acquisition of InfuSystem